Health Sciences Acquisitions, a blank check company targeting the biopharma and medical technology sectors, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
The New York, NY-based company plans to raise $100 million by offering 10 million units at a price of $10. At $10, Health Sciences Acquisitions would command a market value of $125 million. The units consist of one share of common stock and one warrant to purchase half a share of common stock at $11.50 per whole share.
Health Sciences Acquisitions was founded in 2018 and plans to list on the Nasdaq under the symbol HSACU. Chardan Capital Markets and UBS Investment Bank are the joint bookrunners on the deal.
